The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies that “offer extraordinary potential to save lives, but are also associated with extraordinary costs.” In a letter to CMS, AHA recommended immediate and longer-term actions to “promote beneficiary access to these therapies, set appropriate precedents for how they are handled in rating setting and preserve opportunities for additional payment options in the future.” On Friday, CMS proposed that Medicare cover CAR T therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services this week released final Medicare Advantage data on services provided to beneficiaries in calendar year 2015.
Headline
The Aspen Institute recently chose AHA Senior Vice President and Chief Medical Officer Jay Bhatt, D.O., to participate in its Health Innovators Fellowship.
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The House Ways and Means Committee today launched a health task force to better address the needs of residents in rural and underserved communities.
Blog
In this AHA Stat Blog, Jay Bhatt, senior vice president and chief medical officer of the AHA, looks at last year’s Innovation Challenge winners and how they…
Headline
The AHA and the Department of Homeland Security July 17 at 1 p.m. ET will host a webinar discussing current cybersecurity threats to the health care sector.